keyword
MENU ▼
Read by QxMD icon Read
search

infliximab level

keyword
https://www.readbyqxmd.com/read/28725960/topic-infliximab-injection-for-refractory-rectal-stenosis-in-crohn-s-disease-long-term-follow-up-in-two-patients
#1
Niels Teich, Ingo Wallstabe, Ingolf Schiefke
PURPOSE: TNF blockers are approved for intravenous or subcutaneous systemic therapy of many chronic inflammatory diseases. As it is not possible to achieve a sufficient local clinical improvement through systemic therapy in every patient, diverse approaches of topical therapy using TNF blockers have been investigated in recent years. METHODS: In this paper, we report on long-term clinical results of originator infliximab (IFX) injections into symptomatic combined scarring and inflammatory stenoses of the rectum in two patients with Crohn's disease...
July 19, 2017: International Journal of Colorectal Disease
https://www.readbyqxmd.com/read/28725226/jnk-pathway-associated-phosphatase-dusp22-suppresses-cd4-t-cell-activation-and-th1-th17-cell-differentiation-and-negatively-correlates-with-clinical-activity-in-inflammatory-bowel-disease
#2
Rui Zhou, Ying Chang, Jing Liu, Min Chen, Hongling Wang, Meifang Huang, Shi Liu, Xiaobing Wang, Qiu Zhao
This study aimed to investigate the role of JNK pathway-associated phosphatase (JKAP) in inflammatory bowel disease (IBD). JKAP expression was analyzed in the intestinal mucosa of 81 IBD patients and 25 healthy controls (HCs) by qPCR and immunoblotting. The correlations of JKAP with clinical activity and inflammatory cytokines were performed. JKAP expression before and after infliximab treatment was also measured. CD4(+) T cells were isolated from peripheral blood in active IBD patient and HCs and transduced with lentivirus-encoding JKAP (LV-JKAP), anti-JKAP (LV-anti-JKAP), or empty vector (LV-scramble), and JKAP functions on IBD CD4(+) T cells were subsequently investigated...
2017: Frontiers in Immunology
https://www.readbyqxmd.com/read/28716826/il-10-producing-infliximab-specific-t-cells-regulate-the-antidrug-t-cell-response-in-exposed-patients
#3
Alessandra Vultaggio, Francesca Nencini, Sara Pratesi, Daniele Cammelli, Maria Totaro, Sergio Romagnani, Enrico Maggi, Andrea Matucci
Infliximab (IFX) is a chimeric mAb that can lead to the appearance of anti-drug Abs. Recent research has identified the presence of circulating IFX-specific T cells in treated patients. The aim of the study was to analyze the functional characteristics of IFX-specific T cells, in particular their capability to produce biologically active regulatory cytokines. Drug-stimulated PBMCs or coculture systems were used to detect memory T cells in treated patients. The cytokines produced by IFX-specific T cells, T cell lines, and T cell clones were evaluated at the mRNA and protein levels...
July 17, 2017: Journal of Immunology: Official Journal of the American Association of Immunologists
https://www.readbyqxmd.com/read/28696418/associations-between-functional-polymorphisms-and-response-to-biological-treatment-in-danish-patients-with-psoriasis
#4
N D Loft, L Skov, L Iversen, R Gniadecki, T N Dam, I Brandslund, H J Hoffmann, M R Andersen, R B Dessau, A C Bergmann, N M Andersen, P S Andersen, S Bank, U Vogel, V Andersen
Biological agents including anti-tumor necrosis factor (anti-TNF; adalimumab, infliximab, etanercept) and anti-interleukin-12/13 (IL12/23; ustekinumab) are essential for treatment of patients with severe psoriasis. However, a significant proportion of the patients do not respond to a specific treatment. Pharmacogenetics might be a way to predict treatment response. Using a candidate gene approach, 62 mainly functional single-nucleotide polymorphisms (SNPs) in 44 different genes were evaluated in 478 Danish patients with psoriasis undergoing 376 series of anti-TNF treatment and 230 series of ustekinumab treatment...
July 11, 2017: Pharmacogenomics Journal
https://www.readbyqxmd.com/read/28677139/s100a7-expression-levels-in-coordination-with-interleukin-8-indicate-the-clinical-response-to-infliximab-for-psoriasis-patients
#5
Yasuhiko Sato, Ikko Kajihara, Saori Yamada-Kanazawa, Masatoshi Jinnin, Hironobu Ihn
No abstract text is available yet for this article.
July 2017: Journal of Dermatology
https://www.readbyqxmd.com/read/28676840/improvement-of-arterial-wall-lesions-in-parallel-with-decrease-of-plasma-pentraxin-3-levels-in-a-patient-with-refractory-takayasu-arteritis-after-treatment-with-tocilizumab
#6
Shiho Iwagaitsu, Taio Naniwa
A 19-year-old Japanese woman with active Takayasu arteritis despite multiple conventional immunosuppressive therapies with glucocorticoids in combination with intravenous cyclophosphamide, azathioprine, or infliximab with methotrexate and tacrolimus was successfully treated by switching from infliximab to intravenous tocilizumab. Worsening of claudication of the legs and elevated acute phase reactants, including plasma pentraxin-3 levels, were observed during combination therapy with infliximab. Computed tomography demonstrated increased wall thickening with contrast enhancement in the preexisting lesion of the descending aorta and the femoral arteries...
2017: Case Reports in Rheumatology
https://www.readbyqxmd.com/read/28674134/test-accuracy-of-drug-and-antibody-assays-for-predicting-response-to-antitumour-necrosis-factor-treatment-in-crohn-s-disease-a-systematic-review-and-meta-analysis
#7
Karoline Freeman, Sian Taylor-Phillips, Martin Connock, Rachel Court, Alexander Tsertsvadze, Deepson Shyangdan, Peter Auguste, Hema Mistry, Ramesh Arasaradnam, Paul Sutcliffe, Aileen Clarke
OBJECTIVE: To present meta-analytic test accuracy estimates of levels of antitumour necrosis factor (anti-TNF) and antibodies to anti-TNF to predict loss of response or lack of regaining response in patients with anti-TNF managed Crohn's disease. METHODS: MEDLINE, Embase, the Cochrane Library and Science Citation Index were searched from inception to October/November 2014 to identify studies which reported 2×2 table data of the association between levels of anti-TNF or its antibodies and clinical status...
July 2, 2017: BMJ Open
https://www.readbyqxmd.com/read/28659928/gestational-diabetes-mellitus-is-associated-with-altered-neutrophil-activity
#8
Maria Stoikou, Franco Grimolizzi, Stavros Giaglis, Günther Schäfer, Shane Vontelin van Breda, Irene Mathilde Hoesli, Olav Lapaire, Evelyn A Huhn, Paul Hasler, Simona W Rossi, Sinuhe Hahn
Gestational diabetes mellitus (GDM) is a unique form of glucose intolerance, in that it is transient and solely occurs in pregnancy. Pregnancies with GDM are at high risk of developing preeclampsia (PE), a leading cause of fetal and maternal morbidity or mortality. Since PE is associated with excessive activation of circulatory neutrophils and occurrence of neutrophil extracellular traps (NETs) in affected placentae, we examined these features in cases with GDM, as this could be a feature linking the two conditions...
2017: Frontiers in Immunology
https://www.readbyqxmd.com/read/28644181/serum-interleukin-9-levels-predict-disease-severity-and-the-clinical-efficacy-of-infliximab-in-patients-with-crohn-s-disease
#9
Ting Feng, Baili Chen, Li Li, Shanshan Huang, Shomron Ben-Horin, Yun Qiu, Rui Feng, Manying Li, Ren Mao, Yao He, Zhirong Zeng, Shenghong Zhang, Minhu Chen
BACKGROUND: Interleukin (IL)-9 drives gut inflammation, but its role in Crohn's disease (CD) is unclear. We aimed to analyze correlations between serum IL-9 levels and disease severity and to evaluate their predictive value in relation to the clinical efficacy of infliximab (IFX) in patients with CD. METHODS: Between January 2013 and December 2015, 100 consecutive patients with active CD and 50 age- and sex-matched control individuals were recruited from a tertiary center...
June 20, 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28637743/knowledge-attitude-and-practice-of-healthcare-professionals-towards-infliximab-and-insulin-glargine-biosimilars-result-of-a-uk-web-based-survey
#10
Stephen R Chapman, Raymond W Fitzpatrick, Mohammed I Aladul
OBJECTIVE: To investigate healthcare professionals' knowledge and attitudes towards infliximab and insulin glargine biosimilars and the factors influencing their prescribing. Then, to compare healthcare professionals' attitudes with the utilisation of these biosimilars in UK hospitals. DESIGN: Self-administered, one-time web-based survey and drug utilisation analysis. SETTING AND DATA SOURCES: Professional associations and societies in the field of dermatology, diabetology, gastroenterology and rheumatology in the UK, between 8 August 2016 and 8 January 2017...
June 21, 2017: BMJ Open
https://www.readbyqxmd.com/read/28629912/calprotectin-and-the-magnitude-of-antibodies-to-infliximab-in-clinically-stable-ulcerative-colitis-patients-are-more-relevant-than-infliximab-trough-levels-and-pharmacokinetics-for-therapeutic-escalation
#11
Fernando Magro, Joana Afonso, Susana Lopes, Rosa Coelho, Raquel Gonçalves, Paulo Caldeira, Paula Lago, Helena Tavares de Sousa, Jaime Ramos, Ana Rita Gonçalves, Paula Ministro, Isadora Rosa, Ana Isabel Vieira, Patrícia Andrade, João-Bruno Soares, Diana Carvalho, Paula Sousa, Tânia Meira, Joanne Lopes, Joana Moleiro, Cláudia Camila Dias, Amílcar Falcão, Karel Geboes, Fatima Carneiro
Although infliximab (IFX) is an efficient therapy for ulcerative colitis (UC) patients, a considerably high rate of therapeutic failures still occurs. This study aimed at a better understanding of IFX pharmacokinetics and pharmacodynamics among clinically-asymptomatic UC patients. This was a multicentric and prospective study involving 65 UC patients in the maintenance phase of IFX therapy. There were no significant differences between patients with positive and negative clinical, endoscopic and histological outcomes concerning their IFX trough levels (TLs), area under the IFX concentration vs...
June 7, 2017: EBioMedicine
https://www.readbyqxmd.com/read/28629363/fibroblast-paracrine-tnf-%C3%AE-signaling-elevates-integrin-a5-expression-in-idiopathic-pulmonary-fibrosis-ipf
#12
Gali Epstein Shochet, Elizabetha Brook, Lilach Israeli-Shani, Evgeny Edelstein, David Shitrit
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with a poor prognosis. Inflammatory cytokines play a significant role in IPF pathology. However, the fibroblast itself is also believed to be the primary effector in IPF. We hypothesized that the fibroblasts themselves secrete pro-inflammatory cytokines that could propagate IPF by affecting normal neighboring cells. Thus, we explored the effects of IPF fibroblast derived media on normal fibroblast characteristics...
June 19, 2017: Respiratory Research
https://www.readbyqxmd.com/read/28618062/examining-maintenance-care-following-infliximab-salvage-therapy-for-acute-severe-ulcerative-colitis
#13
Dean Seah, Matthew C Choy, Alexandra Gorelik, William R Connell, Miles P Sparrow, Daniel van Langenberg, Geoffrey Hebbard, Gregory Moore, Peter De Cruz
BACKGROUND AND AIMS: Data supporting the optimal maintenance drug therapy & strategy to monitor ongoing response following successful infliximab (IFX) induction, for acute severe ulcerative colitis (ASUC), are limited. We aimed to evaluate maintenance & monitoring strategies employed in patients post IFX induction therapy. METHODS: Patients in 6 Australian tertiary centres treated with IFX for steroid-refractory ASUC between April 2014 & May 2015 were identified via hospital IBD & pharmacy databases...
June 15, 2017: Journal of Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/28617758/individualized-infliximab-treatment-guided-by-patient-managed-ehealth-in-children-and-adolescents-with-inflammatory-bowel-disease
#14
Katrine Carlsen, Gunnar Houen, Christian Jakobsen, Thomas Kallemose, Anders Paerregaard, Lene B Riis, Pia Munkholm, Vibeke Wewer
BACKGROUND: To individualize timing of infliximab (IFX) treatment in children and adolescents with inflammatory bowel disease (IBD) using a patient-managed eHealth program. METHODS: Patients with IBD, 10 to 17 years old, treated with IFX were prospectively included. Starting 4 weeks after their last infusion, patients reported a weekly symptom score and provided a stool sample for fecal calprotectin analysis. Based on symptom scores and fecal calprotectin results, the eHealth program calculated a total inflammation burden score that determined the timing of the next IFX infusion (4-12 wk after the previous infusion)...
June 14, 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28611632/infliximab-induced-aseptic-meningitis-during-the-treatment-of-psoriatic-arthritis
#15
Yuki Matsuura-Otsuki, Takaaki Hanafusa, Hiroo Yokozeki, Kyoko Watanabe
A 42-year-old Japanese man presented with persistent headache during treatment for psoriatic arthritis (PsA) with infliximab. Treatment with infliximab was initiated 3 years before and the psoriatic skin lesions with arthritis were well controlled. However, after 21 doses of infliximab, the skin lesions and joint pain exacerbated and became intractable. Ten days after the dosage of infliximab was increased, the patient experienced headache and nausea with high fever. He had scaly, well-circumscribed erythemas on his trunk, extremities, and deformed nails...
May 2017: Case Reports in Dermatology
https://www.readbyqxmd.com/read/28604144/anti-tnf-%C3%AE-effects-on-anemia-in-rheumatoid-and-psoriatic-arthritis
#16
Addolorata Corrado, Valeria Di Bello, Francesca d'Onofrio, Nicola Maruotti, Francesco Paolo Cantatore
A key role in the pathogenesis of rheumatoid arthritis (RA) and psoriatic arthritis (PsA) is played by inflammatory cytokines, including tumor necrosis factor-α (TNF-α), which are also involved in inducing inflammatory anemia. We have followed 67 RA patients and 64 PsA patients for 1 year to evaluate the effects of TNF-α inhibitors on disease activity and on inflammatory anemia. Patients were divided into three different treatment groups, according to a randomized assignment to receive therapy with etanercept, adalimumab, or infliximab...
June 1, 2017: International Journal of Immunopathology and Pharmacology
https://www.readbyqxmd.com/read/28593609/therapeutic-drug-monitoring-tdm-as-a-tool-in-the-switch-from-infliximab-innovator-to-biosimilar-in-rheumatic-patients-results-of-a-12-month-observational-prospective-cohort-study
#17
E M H Schmitz, S Benoy-De Keuster, A J L Meier, V Scharnhorst, R A M Traksel, M A C Broeren, L J J Derijks
The objective of this study is to apply therapeutic drug monitoring (TDM) as an objective tool to monitor the switch from infliximab innovator (INX) to infliximab biosimilar (INB) in our diverse rheumatic cohort in daily clinical practice. All rheumatic patients on INX treatment (Remicade®) and ≥18 years were switched to INB (Inflectra®) as part of routine care, but in a controlled setting. Patients were monitored by taking blood samples just before the first infusion of INB (T1), and after the second (T2), fourth (T3), and seventh (T4) infusion of INB...
June 7, 2017: Clinical Rheumatology
https://www.readbyqxmd.com/read/28561325/assays-for-infliximab-drug-levels-and-antibodies-a-matter-of-scales-and-categories
#18
L Bader, S M Solberg, S H Kaada, N Bolstad, D J Warren, S Gavasso, C G Gjesdal, C A Vedeler
Immunogenicity is a frequent cause of secondary non-response to tumor necrosis factor (TNF) inhibitors. Drug level measurement and detection of anti-drug antibodies has been shown to be cost-effective and clinically relevant, and a large number of assays are available for these purposes. It is, however, difficult to compare assays and translate results into clinical meaningful information due to different methodological approaches and a lack of assay standardization. We have analyzed infliximab drug levels and anti-drug antibodies in 107 patient samples using enzyme-linked immunoassays (ELISA), immunofluorometric assays (IFMA), and reporter gene assays (RGA) for drug and for antibody...
May 31, 2017: Scandinavian Journal of Immunology
https://www.readbyqxmd.com/read/28524434/unaffected-reaction-level-in-tuberculin-skin-test-by-long-term-therapy-with-tumor-necrosis-factor-inhibitors-for-rheumatoid-arthritis
#19
Shotaro Yamamoto, Katsuya Nagatani, Takeo Sato, Masahiro Iwamoto, Shino Takatori, Seiji Minota
AIM: The tuberculin skin test (TST) is used to diagnose tuberculosis; however, the influence of tumor necrosis factor (TNF) inhibitors on the test is unclear. This study investigated whether therapy with TNF inhibitors suppresses the TST reaction due to immunosuppression or whether the TST reaction increases due to reactivation of latent Mycobacterium tuberculosis infection. METHOD: Ninety-one patients with rheumatoid arthritis receiving TNF inhibitors (40 using infliximab and 51 using etanercept) were studied...
May 19, 2017: International Journal of Rheumatic Diseases
https://www.readbyqxmd.com/read/28522947/clinical-efficacy-of-adalimumab-versus-infliximab-and-the-factors-associated-with-recurrence-or-aggravation-during-treatment-of-anal-fistulas-in-crohn-s-disease
#20
Cheng-Chun Ji, Shota Takano
BACKGROUND/AIMS: Infliximab has proven to be effective in the treatment of perianal fistulas in Crohn's disease (CD) but the efficacy of adalimumab is still unclear. The aim of this study is to assess the clinical efficacy of adalimumab and compare the results with those for infliximab. METHODS: Forty-seven CD patients treated for perianal fistulas with infliximab from September 2005 to December 2010 (n=31), or with adalimumab from November 2010 to May 2012 (n=16), were enrolled in this retrospective study...
April 2017: Intestinal Research
keyword
keyword
53792
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"